PAX Paxman AB (publ)
Paxman AB (publ), together with its subsidiaries, provides cryotherapy solutions in the United Kingdom, Europe, North and South America, Oceania, and Asia. The company offers Paxman scalp cooling system, a mechanized form of scalp cooling for the prevention of chemotherapy-induced alopecia. It also engages in the development of a medical cryocompression device for the prevention of chemotherapy-induced peripheral neuropathy. The company was founded in 1996 and is based in Karlshamn, Sweden.…
Industry Peers
Medical DevicesKey Statistics
About Paxman (STO: PAX)
›
Paxman (STO: PAX) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 151 employees.
The shares were at 68.50 SEK on 19 November 2026, up 5.4% over 52 weeks. Its 52-week range is 41.00 SEK to 69.90 SEK: the price is 2.0% below the high and 67.1% above the low.
Its market capitalisation is 1.59B SEK.
Paxman reports return on equity of -4.1%, an operating margin of 0.4% and revenue up 40.3% year over year.
It holds more cash than debt, a net cash position of 93.26M SEK. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 2 analysts cover the stock; their mean price target of 96.00 SEK is 40.1% above the current price.